Synact Pharma's Covid-19 disease trials cheaper than expected

Listed company Synact Pharma has moved a study from Europe to Brazil and significantly lowers the expected costs of the trial that tests the company's main candidate as a supplementary treatment for Covid-19 patients.

Synact Pharma's CFO Henrik Stage (left), CEO direktør Jeppe Øvlesen (middle) and CSO Thomas Jonassen (right). Photo: Synact Pharma Photo: Synact Pharma / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles